- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02608879
Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis (OMDP)
Study Overview
Status
Conditions
Detailed Description
Oral mucositis (OM) is one of the most debilitating adverse effects in cancer patients treated with chemotherapy or radiation (RT). Currently, there are no effective therapies or prevention for mucositis, while several clinical studies have suggested that professional oral care could effectively reduce the severity of Radiation Therapy or chemotherapy-induced oral mucositis. Palliative treatment, rather than preventive or curative measures, remains the standard of care. Evidence-based guidelines do not provide consistent recommendations for the prevention, treatment and management of oral mucositis.
The investigators hypothesize that a monitored regimen of professional oral hygiene prevents harmful ecological shifts in the oral cavity, improve oral health and reduce the duration and severity of Oral Mucositis in cancer patients, consequently improving their overall quality of life during treatment. Moreover, the investigators hypothesize that the weekly oral hygiene regimen performed by an oral health professional is more effective in treating and preventing mucositis than current standard-of-care treatments.
The principal investigator of this project has developed a novel oral care regimen protocol for the treatment of oral mucositis. The "Oral Mucosa Deterging and Periodontal Debridement" (OMDP) protocol consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the debridement of the periodontium and deterging of the oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation. Co-adjuvant treatments such as intense fluoride treatments, oral hygiene instructions and palliative mouth-rinses are also part of the protocol. The hypothesis is that repeated professional prophylaxis of the oral cavity would protect the healthy oral tissue against infection and inflammation often associated with severe cases of mucositis, and consequently reduces mucositis incidence and duration.
Participants in this study would attend approximately 9 study visits over the course of 16-18 weeks, depending on their specific cancer treatment plan. Study participants will be randomized to receive either the oral health protocol, which they will receive on a weekly basis, or standard of care oral hygiene instructions and tooth brushing, preformed on a bi-weekly basis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patient aged 18 years or older;
- Patients must sign an informed consent before data collection, screening, or initiation of study procedures;
- Patients who are scheduled to undergo radiation or chemoradiation treatment for head/neck cancer;
- Patients who have a minimum of 6 natural teeth at the time of enrollment.
Exclusion Criteria:
- Female patients who are pregnant or lactating at the baseline/screening visit;
- Patient participating in another biomedical/oral health research study that would interfere with participating in this study;
- Patient deprived of freedom, under supervision or guardianship;
- Patient unable to attend to scheduled medical monitoring due to geographical, social or mental reasons;
- Immune compromised or other serious medical conditions, regardless of whether the condition is controlled or not;
- Patient who requires pre-medication prior to dental treatment;
- Any patient, in the opinion of the Investigator, who is unable or unlikely to comply fully with the study requirements or procedures for any reason (e.g. major surgical resection of intra-oral structures which would prevent oral care intervention, edentulous, severe periodontal disease, etc).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OMDP Group
Subjects randomized to this group will attend weekly visits and receive a full dental cleaning, as well as have their gums/tongue cleaned by a dental professional.
Subjects will also receive standard of care oral hygiene instructions.
|
OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa.
This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
An ultrasonic dental scaler will be used to clean the teeth
Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
|
Other: Control Group
Subjects assigned to the control group will receive standard of care oral health instructions and will come for bi-weekly treatment visits where they will have their teeth cleaned (brushed) by a dental professional.
|
Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home.
Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oral Mucositis Severity - WHO Scale
Time Frame: End of Radiation Treatment (approximately week 7)
|
OM severity will be assessed by the WHO Oral Mucositis Scale at each follow-up visit. The WHO Oral Mucositis Scale is a 5 point scale (0 to 4) with the following scoring system: 0=None
|
End of Radiation Treatment (approximately week 7)
|
Oral Mucositis Severity - NCI Scale
Time Frame: End of Radiation Treatment (approximately week 7)
|
OM severity will be assessed by the NCI-CTCAE Scale (National Cancer Institute - Common Toxicity Criteria and Grading of Adverse Events) at each follow-up visit. The NCI-CTCAE is a 5 point scale (1-5) with the following grading system:
|
End of Radiation Treatment (approximately week 7)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Level of Oral Pain (FACES Scale)
Time Frame: End of Radiation Treatment (approximately week 7)
|
The FACES Scale is a 6 point scale which ranges from 0-10 (and includes even numbers only). The scale is accompanied by illustrations of faces which represent each score. The subjects is shown the scale and asked to choose the face that best depicts the pain they are experiencing. 0=No hurt 2=Hurts a little bit 4=Hurts a little more 6=Hurts even more 8=Hurts a whole lot 10-Hurts the worst you could imagine |
End of Radiation Treatment (approximately week 7)
|
Mean Difference in the Relative Abundance of Oral Microbial Species of the Cheek (Right Side) From Baseline to Onset of Oral Mucositis
Time Frame: Baseline to Onset of Oral Mucositis
|
The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area. A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis. For this data, the top five most abundant microbial species are presented. |
Baseline to Onset of Oral Mucositis
|
Mean Difference in the Relative Abundance of Oral Microbial Species of the Cheek (Left Side) From Baseline to Onset of Oral Mucositis
Time Frame: Baseline to Onset of Oral Mucositis
|
The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area. A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis. For this data, the top five most abundant microbial species are presented. |
Baseline to Onset of Oral Mucositis
|
Mean Difference in the Relative Abundance of Oral Microbial Species of the Tongue (Right Side) From Baseline to Onset of Oral Mucositis
Time Frame: Baseline to Onset of Oral Mucositis
|
The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area. A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis. For this data, the top five most abundant microbial species are presented. |
Baseline to Onset of Oral Mucositis
|
Mean Difference in the Relative Abundance of Oral Microbial Species of the Tongue (Left Side) From Baseline to Onset of Oral Mucositis
Time Frame: Baseline to Onset of Oral Mucositis
|
The number of each type of microbial species will be quantified and compared at each follow-up visit. Relative abundance for each species will be measured and reported. Relative abundance is a measure of the proportion of an organism of a particular kind (in this case, each microbial species) relative to the total number of organisms (the other microbial species) in the area. A positive mean value indicates that the species was present in greater quantities at baseline. A negative mean value indicates that the species was present in greater quantities at onset of oral mucositis. For this data, the top five most abundant microbial species are presented. |
Baseline to Onset of Oral Mucositis
|
Change in the Level of Salivary Proinflammatory Cytokines From Baseline to 16 Weeks
Time Frame: Baseline and 16 weeks (final study visit)
|
The level of salivary proinflammatory cytokines will be compared between the two groups at each follow-up visit.
|
Baseline and 16 weeks (final study visit)
|
Change in Quality of Life as Measured by the Composite Score of the EORTC
Time Frame: Baseline to the peak of mucositis (approximately week 4)
|
Quality of life will be measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC) and Head & Neck module (EORTC-H&N) and compared between the two groups at each follow-up visit. There is not a single composite score for the entire questionnaire, but rather composite scores for each type of assessment (e.g. physical functioning, global health, swallowing, etc.). Possible scores range from 0-100. A lower score indicates low levels of that trait, which a higher score indicates high levels of that trait (e.g. a 100 for "physical functioning" indicates a high level of physical function). |
Baseline to the peak of mucositis (approximately week 4)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Patricia Corby, DDS, MS, NYU Langone Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-00082
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Cancer
-
Royal Surrey County Hospital NHS Foundation TrustCompleted
-
Centre Francois BaclesseTerminatedCancer | Cognitive Function | Compliance | Oral TherapiesFrance
-
University of WashingtonBlaze Bioscience Inc.RecruitingStage III Lip and Oral Cavity Cancer AJCC v8 | Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer AJCC v8United States
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Oral LeukoplakiaUnited States
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Stage 0 Lip and Oral Cavity Cancer | Stage 0 Oropharyngeal CancerUnited States
-
Dana-Farber Cancer InstituteCompletedBreast Cancer | Gastrointestinal Cancer | Oral Cancer Directed Therapy | Oral ChemotherapyUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Lip and Oral Cavity Squamous Cell Carcinoma | Oral Cavity Verrucous Carcinoma | Stage 0 Lip and Oral Cavity CancerUnited States
-
University of British ColumbiaRecruiting
-
Istituto Scientifico Romagnolo per lo Studio e...Kessler FoundationUnknownCancer | Oral Drug AdministrationItaly
-
Centre Francois BaclesseLigue contre le cancer, FranceCompletedManagement of Oral Care and Cancer in Palliative SituationFrance
Clinical Trials on Oral Mucosa Deterging and Periodontal Debridement (OMDP)
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Aga Khan UniversityCompletedBirth Weight | Birth, PretermPakistan
-
University of PennsylvaniaMedical University of South Carolina; NYU Langone Health; National Institute... and other collaboratorsTerminatedHead and Neck Cancer | Oral MucositisUnited States
-
University of TriesteUnknownPeriodontal Diseases | Anticoagulant-induced BleedingItaly
-
University Hospital, ToulouseUniversity Paul Sabatier of ToulouseTerminated
-
University of Nove de JulhoCompleted
-
King's College LondonRecruitingPeriodontitis | Surgical Procedure, Unspecified | Furcation DefectsUnited Kingdom
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedChronic Periodontitis ComplexBrazil
-
Universidad Autonoma de San Luis PotosíHospital Central "Dr. Ignacio Morones Prieto"Unknown
-
King's College LondonActive, not recruitingPeriodontitis | Surgical Procedure, Unspecified | Furcation Defects | Periodontal Bone LossUnited Kingdom